David H. Aggen

Also affiliated with Cornell University, Kettering University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

1.8Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1283

Top 12%

1.8DataRank

Top 12%68 citations

Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Düzgöl, Samuel A. Funt +18 more

Papers

Driven by 19 papers — median percentile 88. Top paper: “Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages”.

Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages

Cell(2021)10.1016/j.cell.2021.04.038

N/A

9.0DataRank · unranked

379 citations

Nivedita Chowdhury, Scott M. Haake, Casey R. Ager, Vinson Wang, Lukas Vlahos +12 more

Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1610

N/A

3.7DataRank · unranked

130 citations

Casey R. Ager, Aleksandar Obradović, Nivedita Chowdhury, Ali Ghasemzadeh, Wendy Mao +11 more

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.01485

N/A

3.3DataRank · unranked

100 citations

Michael Lattanzi, Karissa Whiting, Hikmat Al‐Ahmadie, Colleen Quinlan, Min Yuen Teo +34 more

Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1283

Top 12%

1.8DataRank

Top 12%68 citations

Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Düzgöl, Samuel A. Funt +18 more

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

Journal of Clinical Oncology(2025)10.1200/jco-25-01608

N/A

0.674DataRank · unranked

20 citations

Matthew D. Galsky, Nazlı Dizman, David H. Aggen, Neeraj Agarwal, Hikmat Al‐Ahmadie +39 more

Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy

The Prostate(2020)10.1002/pros.23948

N/A

0.629DataRank · unranked

13 citations

Samuel Pan, William D. Figg, Zoila A. Lopez‐Bujanda, Jonathan D. Strope, David H. Aggen +6 more

Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial

European Urology(2024)10.1016/j.eururo.2024.04.025

N/A

0.542DataRank · unranked

36 citations

Chung-Han Lee, Martin H. Voss, Maria I. Carlo, Andrea Knezevic, Laura Peralta +11 more

A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer

European Urology Oncology(2023)10.1016/j.euo.2023.10.017

N/A

0.416DataRank · unranked

15 citations

Sahil D. Doshi, Andrea Knežević, Joshua Chaim, Ying‐Bei Chen, Rachel Jacobi +14 more

Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma

European Urology(2024)10.1016/j.eururo.2024.10.024

N/A

0.385DataRank · unranked

12 citations

Syed M. Alam, Fengshen Kuo, Ziyu Chen, Wesley Yip, Andrew Katims +34 more

Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer

Nature Communications(2025)10.1038/s41467-025-67643-2

N/A

0.292DataRank · unranked

6 citations

Xinran Tang, Jordan Eichholz, Andrew McPherson, Jasmine Thomas, Karan Nagar +23 more

Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer

JCO Precision Oncology(2024)10.1200/po.23.00274

N/A

0.292DataRank · unranked

6 citations

Karissa Whiting, Vignesh Ravichandran, Jacob E. Tallman, Syed M. Alam, Carissa Chu +29 more

Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4526

N/A

0.269DataRank · unranked

5 citations

Jatin Gandhi, Min Yuen Teo, Michael Lattanzi, Samuel A. Funt, David H. Aggen +14 more

Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4598

N/A

0.165DataRank · unranked

2 citations

Neha Ratna, David Gavrilov, Cihan Düzgöl, Mahnoor Akhlaq, Min Yuen Teo +15 more

Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4584

N/A

0.165DataRank · unranked

2 citations

Alexander Solovyov, Jayon Lihm, Colleen Quinlan, Karissa Whiting, Hao Li +15 more

A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma

European Urology Oncology(2025)10.1016/j.euo.2025.03.010

N/A

0.104DataRank · unranked

1 citations

Sahil D. Doshi, Andrea Knežević, Rachel Jacobi, Hyung Jun Woo, David H. Aggen +13 more

Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.498

N/A

0DataRank · unranked

12 citations

Eugene J. Pietzak, Samantha Brown, Jie‐Fu Chen, Vanessa Peters, Ashley Marie Regazzi +15 more

Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e16519

N/A

0DataRank · unranked

0 citations

Min Yuen Teo, Samuel A. Funt, Chung‐Han Lee, David H. Aggen, Neha Ratna +11 more

Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3882

N/A

0DataRank · unranked

23 citations

Carissa Chu, Jonathan E. Rosenberg, David H. Aggen

Data from Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses

(2023)10.1158/1078-0432.c.6530295

N/A

0DataRank · unranked

0 citations

Casey R. Ager, Aleksandar Obradović, Nivedita Chowdhury, Ali Ghasemzadeh, Wendy L. Mao +11 more

David H. Aggen

Indexed papers

Top data-sharing exemplar

Papers